Page last updated: 2024-12-07
2,5-diketogluconic acid
Description
2,5-Diketogluconic acid (2,5-DKG) is a dicarboxylic acid derived from glucose. It is a potent chelator of metal ions, particularly iron, and has shown promise as a potential therapeutic agent for iron overload disorders. 2,5-DKG is synthesized through the oxidation of glucose using various enzymatic or chemical methods. Its ability to chelate iron has been investigated for its potential in treating iron overload conditions such as hemochromatosis and thalassemia. Additionally, 2,5-DKG exhibits antimicrobial activity against certain bacteria. Ongoing research focuses on exploring its potential applications in medicine, agriculture, and other fields.'
2,5-diketogluconic acid: RN given refers to (D-threo)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 102287 |
| CHEBI ID | 18281 |
| SCHEMBL ID | 379863 |
| MeSH ID | M0101693 |
Synonyms (18)
| Synonym |
|---|
| 2,5-dioxo-d-gluconic acid |
| CHEBI:18281 |
| d-threo-hexo-2,5-diulosonic acid |
| 2,5-didehydro-d-gluconic acid |
| 2,5-diketo-d-gluconic acid |
| d-threo-2,5-hexodiulosonic acid |
| 2595-33-7 |
| C02780 , |
| 2,5-diketogluconic acid |
| hexo-2,5-diulosonic acid |
| (3s,4s)-3,4,6-trihydroxy-2,5-dioxohexanoic acid |
| einecs 219-992-3 |
| RXMWXENJQAINCC-DMTCNVIQSA-N |
| SCHEMBL379863 |
| LMFA01050471 |
| DTXSID30936065 |
| Q27102964 |
| (3s,4s)-3,4,6-trihydroxy-2,5-dioxohexanoicacid |
Roles (1)
| Role | Description |
|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| diketoaldonic acid | Dioxo carboxylic acids formally derived from aldoses by replacement of two secondary CHOH groups by carbonyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.23 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.18 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |